Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, CMS says
03:17pm, Wednesday, 08'th Jan 2025
Medicare drug plans can now cover Eli Lilly's blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare & Medicaid Services confirmed to CNBC. That opens the door for bro
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
09:45am, Wednesday, 08'th Jan 2025
Eli Lilly (LLY -0.27%) and Novo Nordisk (NVO 2.04%) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications. They are also big
Top pharmaceutical stocks to buy in 2025
03:00am, Wednesday, 08'th Jan 2025
Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
06:51pm, Tuesday, 07'th Jan 2025
In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.
Lilly to participate in J.P. Morgan Healthcare Conference
10:00am, Tuesday, 07'th Jan 2025
INDIANAPOLIS , Jan. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025.
GLP-1 makers could be under pressure in 2025
07:29pm, Monday, 06'th Jan 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk what is next for the obesity drug makers in 2025.
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
09:00am, Monday, 06'th Jan 2025
Tyrzepatide seems more effective than semaglutide, but the market for slimming drugs is quite large for both. Both companies have a dominant position in their industry and a solid financial position,
7 Investments To Avoid In 2024: The Reckoning
04:33am, Sunday, 05'th Jan 2025
As is usual at the start of a new year, many Seeking Alpha contributors will have their lists of where to put your money during the next year. But not losing money with your investments is almost as i
Prediction: These 3 Healthcare Stocks Will Soar in 2025
06:48am, Saturday, 04'th Jan 2025
No one knows for sure what the new year will hold for the market. However, some stocks' chances for success look particularly good.
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
12:06pm, Friday, 03'rd Jan 2025
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 03'rd Jan 2025
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
03:46am, Friday, 03'rd Jan 2025
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
02:18pm, Thursday, 02'nd Jan 2025
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and di
5 Large Drug Stocks to Keep An Eye On in the New Year
10:02am, Thursday, 02'nd Jan 2025
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retain
Lilly's Obesity Drug Zepbound To Be Key Health Cost Driver For 2025
01:00pm, Wednesday, 01'st Jan 2025
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers, employers and government health programs who cover it in 2025.
